Generic placeholder image

Current Cancer Drug Targets

Author(s): Muhammad Imran Qadir*, Muhammad Shahid Iqbal and Rimsha Khan

DOI: 10.2174/1568009622666220427121127

DownloadDownload PDF Flyer Cite As
β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer

Page: [537 - 540] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Cancer, one of the major health problems all over the world, requires more competent drugs for clinical use. One recent possible chemotherapeutic drug under research is β-lapachone. β- lapachone (1,2-naphthoquinone) has promising activity against those tumors showing raised levels of Nicotinamide di-phosphate Quinone Oxidoreductases-1 (NQO1). NQO1 is found to be up-regulated in pancreatic tumor cells, and thus β-lapachone could generate cytotoxicity in various cancers like pancreatic tumors. β-lapachone harborage independent growth and clonogenic cell survival in agar. The cell-killing effects of β-lapachone can be stopped by using dicumarol, an inhibitor of NAD(P)H Quinone Oxidoreductases-1. In previously established pancreatic cancer xenografts in mice, β- lapachone inhibited the tumor growth when given orally rather than when combined with cyclodextrin to improve its bioavailability.

Keywords: NAD(P)H quinone oxidoreductase-1, β-lapachone, reactive oxygen species, quinones, cyclodextrins, human pancreatic cancer.

Graphical Abstract

[1]
Gomes, C.L.; de Albuquerque Wanderley Sales, V.; Gomes de Melo, C.; Ferreira da Silva, R.M.; Vicente Nishimura, R.H.; Rolim, L.A.; Rolim Neto, P.J. Beta-lapachone: Natural occurrence, physicochemical properties, biological activities, toxicity and synthesis. Phytochemistry, 2021, 186, 112713.
[http://dx.doi.org/10.1016/j.phytochem.2021.112713] [PMID: 33667813]
[2]
Beg, M.S.; Huang, X.; Silvers, M.A.; Gerber, D.E.; Bolluyt, J.; Sarode, V.; Fattah, F.; Deberardinis, R.J.; Merritt, M.E.; Xie, X.J.; Leff, R.; Laheru, D.; Boothman, D.A. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. J. Surg. Oncol., 2017, 116(1), 83-88.
[http://dx.doi.org/10.1002/jso.24624] [PMID: 28346693]
[3]
Yang, Y.P.; Qi, F.J.; Qian, Y.P.; Bao, X.Z.; Zhang, H.C.; Ma, B.; Dai, F.; Zhang, S.X.; Zhou, B. Developing push-pull hydroxylphenylpolyenylpyridinium chromophores as ratiometric two-photon fluorescent probes for cellular and intravital imaging of mitochondrial NQO1. Anal. Chem., 2021, 93(4), 2385-2393.
[http://dx.doi.org/10.1021/acs.analchem.0c04279] [PMID: 33439630]
[4]
Chen, Y.; Liu, Y.; Chen, C.; Lv, J.; Zhang, J.; Li, G. An electrochemical method to assay the activity of NAD (P) H: Quinone oxidoreductase 1. Sens. Actuators B Chem., 2015, 216, 343-348.
[http://dx.doi.org/10.1016/j.snb.2015.04.059]
[5]
Zhang, Y.; Knatko, E.V.; Higgins, M.; Dayalan Naidu, S.; Smith, G.; Honda, T.; de la Vega, L.; Dinkova-Kostova, A.T. Pirin, an Nrf2-regulated protein, is overexpressed in human colorectal tumors. Antioxidants, 2022, 11(2), 262.
[http://dx.doi.org/10.3390/antiox11020262] [PMID: 35204145]
[6]
Ross, D.; Siegel, D. The diverse functionality of NQO1 and its roles in redox control. Redox Biol., 2021, 41, 101950.
[http://dx.doi.org/10.1016/j.redox.2021.101950] [PMID: 33774477]
[7]
Zhang, Y.; Zhang, G.; Zeng, Z.; Pu, K. Activatable molecular probes for fluorescence-guided surgery, endoscopy and tissue biopsy. Chem. Soc. Rev., 2022, 51, 566-593.
[http://dx.doi.org/10.1039/D1CS00525A]
[8]
Zhang, L. Chen, Z.; Yang, K.; Liu, C.; Gao, J.; Qian, F. β-Lapachone and paclitaxel combination micelles with improved drug encapsulation and therapeutic synergy as novel nanotherapeutics for NQO1-targeted cancer therapy. Mol. Pharm., 2015, 12(11), 3999-4010.
[http://dx.doi.org/10.1021/acs.molpharmaceut.5b00448] [PMID: 26415823]
[9]
Ke, L.I.A.O.; Fang, N.I.U.; Hai-Ping, H.A.O.; Guang-Ji, W.A.N.G. Advances on structure-activity relationship of NQO1-targeting antitumor quinones. Chin. J. Nat. Med., 2012, 10(3), 170-176.
[http://dx.doi.org/10.3724/SP.J.1009.2012.00170]
[10]
Silvers, M.A.; Deja, S.; Singh, N.; Egnatchik, R.A.; Sudderth, J.; Luo, X.; Beg, M.S.; Burgess, S.C.; DeBerardinis, R.J.; Boothman, D.A.; Merritt, M.E. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. J. Biol. Chem., 2017, 292(44), 18203-18216.
[http://dx.doi.org/10.1074/jbc.M117.813923] [PMID: 28916726]
[11]
Moore, Z.; Chakrabarti, G.; Lyssiotis, C.; Deberardinis, R.; David, B.A. Abstract B47: Modulating the NQO1-dependent ‘kiss of death’mechanism of action of NQO1 bioactivatable drugs. 2015, 2015, B47.
[12]
Peng, K.; Liang, B.B.; Liu, W.; Mao, Z.W. What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives. Coord. Chem. Rev., 2021, 449, 214210.
[http://dx.doi.org/10.1016/j.ccr.2021.214210]
[13]
Mahar, R.; Chang, M.C.; Merritt, M.E. Measuring NQO1 Bioactivation Using [2H7]Glucose. Cancers (Basel), 2021, 13(16), 4165.
[http://dx.doi.org/10.3390/cancers13164165] [PMID: 34439319]